XCNQ
INNO
Market cap7mUSD
Sep 17, Last price
2.44CAD
1D
3.83%
1Q
-22.54%
IPO
876.00%
Name
Innocan Pharma Corp
Chart & performance
P/E
—
P/S
0.29
EPS
—
Div yield, %
—
Shrs. gr., 5y
-48.91%
Rev. gr., 5y
406.29%
Revenues
27m
-9.60%
Net income
-1m
L-38.71%
CFO
495k
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems by integrating cannabidiol (CBD) with diverse pharmaceutical ingredients. Its operations extend across the United States, Poland, France, and other international markets. The company actively pursues research and development into CBD-loaded exosomes for treating conditions like COVID-19, as well as advancing CBD-infused liposomes. InnoCan Pharma also commercializes a range of branded CBD-integrated pharmaceutical and topical treatment products, such as CBD eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Established in 2018, the corporation is headquartered in Calgary, Canada.
Key people
Nelson Halpern
Chief Financial Officer · since 2019
Roni Kamhi
Chief Operating Officer · since 2022
Nir Avram
Chief Technology Officer · since 2019
Ron Mayron
Executive Chairman of the Board · since 2019
Iris Bincovich
Chief Executive Officer, Director · since 2019
Yoram Drucker
Executive Vice President - Business Development, Director, Founder · since 2019
Peter Bloch
Independent Director · since 2020
Ralph Bossino
Independent Director · since 2019
Eyal Flom
Independent Director, Corporate Secretary · since 2019
Joshua Lintern
Independent Director · since 2019
Legal address
2400, 525 - 8 Avenue SW
Calgary, AB T2P 1G1
CA
Calgary, AB T2P 1G1
CA
Headquarters
10 Hamanofim St.
Herzliya, TA 4672561
IL
Herzliya, TA 4672561
IL
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||